Windtree Therapeutics Announces CEO Transition and Appointment of New Chief Executive Officer

Windtree Therapeutics, Inc., a Delaware-based biopharmaceutical company listed on the Nasdaq Capital Market under the symbol WINT, disclosed important leadership changes in a recent filing with the Securities and Exchange Commission.

On November 8, 2024, Windtree Therapeutics shared that Craig Fraser, the company’s current President and Chief Executive Officer, will be retiring from his role, effective December 1, 2024. Following his retirement, Mr. Fraser will continue to serve as the Chairman of Windtree’s board of directors. The decision for his retirement was communicated to the Board on November 8, 2024.

In conjunction with Mr. Fraser’s retirement, the company entered into an agreement that spells out the terms of his departure. This includes arrangements for any outstanding compensation, vacation days, and other owed amounts.

Simultaneously, Windtree Therapeutics announced the appointment of Jed Latkin as the incoming President and Chief Executive Officer, effective on the Transition Date. Mr. Latkin, who currently sits on the company’s board, will assume the role of principal executive officer upon taking up his new position. The Board officially sanctioned his appointment on November 8, 2024.

Jed Latkin brings with him a wealth of experience, having served in various executive positions within the biotech and financial sectors. His most recent role was as the Chief Operating Officer and Head of Finance at ProPhase Labs, Inc.

In concurrence with Mr. Latkin’s appointment as the new President and CEO, Windtree Therapeutics finalized an employment agreement with him. The agreement outlines his compensation package, which includes an initial base salary of $557,300, eligibility for bonuses, and potential equity awards.

The agreement also delineates the terms of Mr. Latkin’s employment, including provisions for termination benefits, a non-competition agreement, and indemnification terms.

Furthermore, it’s noted that there are no undisclosed arrangements or relationships that led to Mr. Latkin’s appointment. Windtree Therapeutics assures transparency in its operational and executive processes, emphasizing compliance with regulatory requirements.

The complete text of the agreement will be made available as an exhibit in the company’s Annual Report on Form 10-K for the year ended December 31, 2024.

The succession plan highlights Windtree Therapeutics’ commitment to smooth leadership transitions and continued growth in the biopharmaceutical industry.

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Windtree Therapeutics’s 8K filing here.

Windtree Therapeutics Company Profile

Windtree Therapeutics, Inc, a biotechnology company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. The company’s lead product candidate is istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as for the treatment of early cardiogenic shock.